HC Wainwright Issues Pessimistic Outlook for GENB Earnings

Generate Biomedicines Inc (NASDAQ:GENB) – HC Wainwright decreased their Q3 2026 earnings per share estimates for Generate Biomedicines in a report released on Friday, August 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.55) for the quarter, down from their previous estimate of ($0.52). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Generate Biomedicines’ current full-year earnings is ($2.29) per share. HC Wainwright also issued estimates for Generate Biomedicines’ FY2026 earnings at ($2.16) EPS, Q1 2027 earnings at ($0.58) EPS, Q2 2027 earnings at ($0.51) EPS and Q4 2027 earnings at ($0.50) EPS.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million during the quarter.

GENB has been the topic of a number of other reports. Morgan Stanley boosted their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Generate Biomedicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Trading Up 2.6%

Shares of NASDAQ GENB opened at $14.72 on Tuesday. The firm has a 50 day simple moving average of $14.48. Generate Biomedicines has a 1 year low of $11.00 and a 1 year high of $18.18. The company has a market cap of $1.89 billion and a price-to-earnings ratio of -13.76.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Generate Biomedicines stock. Bank of New York Mellon Corp acquired a new stake in Generate Biomedicines Inc (NASDAQ:GENB) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 57,326 shares of the company’s stock, valued at approximately $967,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.